1. Home
  2. LQDA vs QCRH Comparison

LQDA vs QCRH Comparison

Compare LQDA & QCRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LQDA
  • QCRH
  • Stock Information
  • Founded
  • LQDA 2004
  • QCRH 1993
  • Country
  • LQDA United States
  • QCRH United States
  • Employees
  • LQDA N/A
  • QCRH N/A
  • Industry
  • LQDA Biotechnology: Pharmaceutical Preparations
  • QCRH Major Banks
  • Sector
  • LQDA Health Care
  • QCRH Finance
  • Exchange
  • LQDA Nasdaq
  • QCRH Nasdaq
  • Market Cap
  • LQDA 1.3B
  • QCRH 1.1B
  • IPO Year
  • LQDA 2018
  • QCRH 1993
  • Fundamental
  • Price
  • LQDA $13.17
  • QCRH $64.61
  • Analyst Decision
  • LQDA Strong Buy
  • QCRH Buy
  • Analyst Count
  • LQDA 9
  • QCRH 3
  • Target Price
  • LQDA $27.67
  • QCRH $86.67
  • AVG Volume (30 Days)
  • LQDA 3.0M
  • QCRH 71.3K
  • Earning Date
  • LQDA 08-06-2025
  • QCRH 07-23-2025
  • Dividend Yield
  • LQDA N/A
  • QCRH 0.37%
  • EPS Growth
  • LQDA N/A
  • QCRH N/A
  • EPS
  • LQDA N/A
  • QCRH 6.65
  • Revenue
  • LQDA $14,144,000.00
  • QCRH $324,275,000.00
  • Revenue This Year
  • LQDA $185.38
  • QCRH N/A
  • Revenue Next Year
  • LQDA $350.95
  • QCRH $7.10
  • P/E Ratio
  • LQDA N/A
  • QCRH $9.67
  • Revenue Growth
  • LQDA N/A
  • QCRH N/A
  • 52 Week Low
  • LQDA $8.26
  • QCRH $55.12
  • 52 Week High
  • LQDA $19.41
  • QCRH $96.08
  • Technical
  • Relative Strength Index (RSI)
  • LQDA 36.80
  • QCRH 39.36
  • Support Level
  • LQDA $13.60
  • QCRH $63.68
  • Resistance Level
  • LQDA $14.63
  • QCRH $68.97
  • Average True Range (ATR)
  • LQDA 0.96
  • QCRH 1.23
  • MACD
  • LQDA -0.40
  • QCRH -0.29
  • Stochastic Oscillator
  • LQDA 0.46
  • QCRH 17.58

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

About QCRH QCR Holdings Inc.

QCR Holdings Inc is a multi-bank holding company. The bank operates through segments namely Commercial Banking, Wealth Management, and all other segments. The commercial bank segment is geographically divided by markets namely QCBT, CRBT, CSB, and GB. It generates revenue in the form of interest.

Share on Social Networks: